<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02861417</url>
  </required_header>
  <id_info>
    <org_study_id>2016-0137</org_study_id>
    <secondary_id>NCI-2017-00614</secondary_id>
    <secondary_id>2016-0137</secondary_id>
    <nct_id>NCT02861417</nct_id>
  </id_info>
  <brief_title>Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant</brief_title>
  <official_title>Timed Sequential Busulfan and Post Transplant Cyclophosphamide for Allogeneic Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies the side effect of busulfan, fludarabine phosphate, and
      post-transplant cyclophosphamide in treating patients with blood cancer undergoing donor stem
      cell transplant. Drugs used in chemotherapy, such as busulfan, fludarabine phosphate and
      cyclophosphamide work in different ways to stop the growth of cancer cells, either by killing
      the cells, by stopping them from dividing, or by stopping them from spreading. Giving
      chemotherapy such as busulfan and fludarabine phosphate before a donor stem cell transplant
      helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem
      cells) and cancer cells. Sometimes the transplanted cells from a donor can make an immune
      response against the body's normal cells (called graft-versus-host disease). Giving
      cyclophosphamide after the transplant may stop this from happening. Once the donated stem
      cells begin working, the patient's immune system may see the remaining cancer cells as not
      belonging in the patient's body and destroy them.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:

      I. To assess safety of timed sequential busulfan and fludarabine conditioning regimen and
      post transplant cyclophosphamide as determined by day 100 non-relapse mortality in patients
      undergoing allogeneic transplantation: from matched donors; from mismatched (haploidentical)
      donors.

      SECONDARY OBJECTIVE:

      I. To evaluate efficacy of this therapy and to compare outcomes between recipients of matched
      and mismatched donors by studying the following endpoints: graft versus host disease
      (GVHD)-free/relapse free survival; relapse-free survival; overall survival; non-relapse
      mortality; relapse rate; time to neutrophil and platelet engraftment; incidence of acute and
      chronic GVHD; grade 3 and 4 adverse events.

      TERTIARY OBJECTIVE:

      I. To study impact of timed sequential busulfan therapy and post-transplant cyclophosphamide
      on immune reconstitution and cytokines levels post-transplant.

      OUTLINE: Patients are assigned to 1 of 4 groups.

      GROUP I (FROM HAPLOIDENTICAL DONOR): Patients receive busulfan intravenously (IV) over 3
      hours on days -13, -12, and -6 to -3, thiotepa IV over 4 hours on day -7, fludarabine
      phosphate IV over 1 hour on days -6 to -3. Patients undergo stem cell transplantation IV on
      day 0. Patients then receive cyclophosphamide IV over 3 hours on days 3 and 4. Beginning on
      day 5, patients receive tacrolimus IV continuously or orally (PO) twice daily (BID) for up to
      3 months and mycophenolate mofetil PO thrice daily (TID).

      GROUP II (FROM MATCHED DONOR): Patients receive busulfan IV over 3 hours on days -13, -12,
      and -6 to -3, fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo stem
      cell transplantation IV on day 0. Patients then receive cyclophosphamide IV over 3 hours on
      days 3 and 4. Beginning on day 5, patients receive tacrolimus IV continuously or PO BID for
      up to 3 months.

      GROUP III and GROUP IV: Patients receiving haploidentical related donor transplant, diagnosis
      of myelofibrosis, &gt; 60 years old, or patients with comorbidity scores &gt; 3 will go in Group 3
      or 4. If patients with comorbidity score &gt; 3, then the principal investigator is the final
      arbiter of eligibility for comorbidity score &gt; 3. Busulfan is administered at the dose
      calculated to achieve a total (including first two doses delivered on day -20 and day -13)
      system exposure of 20,000 +/- 12% uMol-min based on the pharmacokinetic studies.

      GROUP V and GROUP VI: Patients receive busulfan IV over 3 hours on days -20, -13, and -6 to
      -3, a lower dose of thiotepa IV over 4 hours on day -7, fludarabine phosphate IV over 1 hour
      on days -6 to -3. Patients undergo stem cell transplantation IV on day 0. Patients then
      receive cyclophosphamide IV over 3 hours on days 3 and 4. Beginning on day 5, patients
      receive tacrolimus IV continuously or PO BID for up to 3 months and mycophenolate mofetil PO
      TID.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 5, 2016</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non-relapse mortality rate</measure>
    <time_frame>100 days</time_frame>
    <description>The proportion of patients with non-relapse mortality will be reported separately by arm, along with the corresponding 95% Bayesian credible interval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Graft versus host disease-free survival/relapse free survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will be calculated from the time of transplant by the method of Kaplan and Meier. Patients with matched donors will be compared to patients with mismatched donors by the log-rank test. Cox proportional hazards regression analysis will be used to assess the association between these survival parameters and clinical and treatment covariates of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will be calculated from the time of transplant by the method of Kaplan and Meier. Patients with matched donors will be compared to patients with mismatched donors by the log-rank test. Cox proportional hazards regression analysis will be used to assess the association between these survival parameters and clinical and treatment covariates of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will be calculated from the time of transplant by the method of Kaplan and Meier. Patients with matched donors will be compared to patients with mismatched donors by the log-rank test. Cox proportional hazards regression analysis will be used to assess the association between these survival parameters and clinical and treatment covariates of interest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The proportion of patients with non-relapse mortality will be reported separately by arm, along with the corresponding 95% Bayesian credible interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse rate</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will be observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to platelet and neutrophil engraftment</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will be calculated from the time of transplant and estimated by the Kaplan-Meier method. Distributions will be compared between patients with matched and mismatched donors via the log-rank test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute and chronic graft versus host disease</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will be estimated using the method of Gooley, and the method of Fine and Gray will be used to model the incidence by disease and clinical characteristics of interest, including matched versus mismatched donors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade 3 and 4 adverse events</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Descriptive statistics will be used to summarize adverse events by treatment arm. The number and proportion of subjects with treatment emergent adverse events will be reported and compared between patients with matched and mismatched donors by using Fisher's exact test. Frequency counts and percentages will also be presented of subjects with serious adverse events and adverse events leading to withdrawal. Graphical summaries will be used where appropriate.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">204</enrollment>
  <condition>Hematopoietic and Lymphoid Cell Neoplasm</condition>
  <condition>High Risk Acute Myeloid Leukemia</condition>
  <condition>High Risk Myelodysplastic Syndrome</condition>
  <condition>Lymphoproliferative Disorder</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Myelodysplastic/Myeloproliferative Neoplasm</condition>
  <condition>Recurrent Acute Lymphoblastic Leukemia</condition>
  <condition>Recurrent Acute Myeloid Leukemia</condition>
  <condition>Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive</condition>
  <condition>Recurrent High Risk Myelodysplastic Syndrome</condition>
  <condition>Recurrent Hodgkin Lymphoma</condition>
  <condition>Recurrent Myelodysplastic Syndrome</condition>
  <condition>Recurrent Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent Plasma Cell Myeloma</condition>
  <arm_group>
    <arm_group_label>Group I (haploidentical donor transplant, chemotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive busulfan IV over 3 hours on days -13, -12, and -6 to -3, thiotepa IV over 4 hours on day -7, fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo stem cell transplantation IV on day 0. Patients then receive cyclophosphamide IV over 3 hours on days 3 and 4. Beginning on day 5, patients receive tacrolimus IV continuously or PO BID for up to 3 months and mycophenolate mofetil PO TID.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II (matched donor transplant, chemotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive busulfan IV over 3 hours on days -13, -12, and -6 to -3, fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo stem cell transplantation IV on day 0. Patients then receive cyclophosphamide IV over 3 hours on days 3 and 4. Beginning on day 5, patients receive tacrolimus IV continuously or PO BID for up to 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group III (haploidentical donor transplant, chemotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving haploidentical related donor transplant, diagnosis of myelofibrosis, &gt; 60 years old, or patients with comorbidity scores &gt; 3 will go in Group 3 or 4. If patients with comorbidity score &gt; 3, then the principal investigator is the final arbiter of eligibility for comorbidity score &gt; 3. Busulfan is administered at the dose calculated to achieve a total (including first two doses delivered on day -20 and day -13) system exposure of 20,000 +/- 12% uMol-min based on the pharmacokinetic studies.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group IV (matched donor transplant, chemotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving haploidentical related donor transplant, diagnosis of myelofibrosis, &gt; 60 years old, or patients with comorbidity scores &gt; 3 will go in Group 3 or 4. If patients with comorbidity score &gt;3, then the principal investigator is the final arbiter of eligibility for comorbidity score &gt; 3. Busulfan is administered at the dose calculated to achieve a total (including first two doses delivered on day -20 and day -13) system exposure of 20,000 +/- 12% uMol-min based on the pharmacokinetic studies.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group V (haploidentical donor transplant, chemotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive busulfan IV over 3 hours on days -20, -13, and -6 to -3, a lower dose of thiotepa IV over 4 hours on day -7, fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo stem cell transplantation IV on day 0. Patients then receive cyclophosphamide IV over 3 hours on days 3 and 4. Beginning on day 5, patients receive tacrolimus IV continuously or PO BID for up to 3 months and mycophenolate mofetil PO TID.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group VI (matched or haploidentical transplant, chemotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving fully matched or haploidentical donor transplant receive busulfan IV over 3 hours on days -20, -13, and -6 to -3, a lower dose of thiotepa IV over 4 hours on day -7, fludarabine phosphate IV over 1 hour on days -6 to -3. Patients undergo stem cell transplantation IV on day 0. Patients then receive cyclophosphamide IV over 3 hours on days 3 and 4. Beginning on day 5, patients receive tacrolimus IV continuously or PO BID for up to 3 months and mycophenolate mofetil PO TID.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo stem cell transplantation</description>
    <arm_group_label>Group I (haploidentical donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group II (matched donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group III (haploidentical donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group IV (matched donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group V (haploidentical donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group VI (matched or haploidentical transplant, chemotherapy)</arm_group_label>
    <other_name>Allogeneic Hematopoietic Cell Transplantation</other_name>
    <other_name>Allogeneic Stem Cell Transplantation</other_name>
    <other_name>HSC</other_name>
    <other_name>HSCT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group I (haploidentical donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group II (matched donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group III (haploidentical donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group IV (matched donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group V (haploidentical donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group VI (matched or haploidentical transplant, chemotherapy)</arm_group_label>
    <other_name>1, 4-Bis[methanesulfonoxy]butane</other_name>
    <other_name>BUS</other_name>
    <other_name>Bussulfam</other_name>
    <other_name>Busulfanum</other_name>
    <other_name>Busulfex</other_name>
    <other_name>Busulphan</other_name>
    <other_name>CB 2041</other_name>
    <other_name>CB-2041</other_name>
    <other_name>Glyzophrol</other_name>
    <other_name>GT 41</other_name>
    <other_name>GT-41</other_name>
    <other_name>Joacamine</other_name>
    <other_name>Methanesulfonic Acid Tetramethylene Ester</other_name>
    <other_name>Methanesulfonic acid, tetramethylene ester</other_name>
    <other_name>Mielucin</other_name>
    <other_name>Misulban</other_name>
    <other_name>Misulfan</other_name>
    <other_name>Mitosan</other_name>
    <other_name>Myeleukon</other_name>
    <other_name>Myeloleukon</other_name>
    <other_name>Myelosan</other_name>
    <other_name>Mylecytan</other_name>
    <other_name>Myleran</other_name>
    <other_name>Sulfabutin</other_name>
    <other_name>Tetramethylene Bis(methanesulfonate)</other_name>
    <other_name>Tetramethylene bis[methanesulfonate]</other_name>
    <other_name>WR-19508</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group I (haploidentical donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group II (matched donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group III (haploidentical donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group IV (matched donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group V (haploidentical donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group VI (matched or haploidentical transplant, chemotherapy)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamide Monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group I (haploidentical donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group II (matched donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group III (haploidentical donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group IV (matched donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group V (haploidentical donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group VI (matched or haploidentical transplant, chemotherapy)</arm_group_label>
    <other_name>Fluradosa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group I (haploidentical donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group II (matched donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group III (haploidentical donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group IV (matched donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group V (haploidentical donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group VI (matched or haploidentical transplant, chemotherapy)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Group I (haploidentical donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group II (matched donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group III (haploidentical donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group IV (matched donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group V (haploidentical donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group VI (matched or haploidentical transplant, chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Group I (haploidentical donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group III (haploidentical donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group V (haploidentical donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group VI (matched or haploidentical transplant, chemotherapy)</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Group I (haploidentical donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group II (matched donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group III (haploidentical donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group IV (matched donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group V (haploidentical donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group VI (matched or haploidentical transplant, chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Group I (haploidentical donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group II (matched donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group III (haploidentical donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group IV (matched donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group V (haploidentical donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group VI (matched or haploidentical transplant, chemotherapy)</arm_group_label>
    <other_name>FK 506</other_name>
    <other_name>Fujimycin</other_name>
    <other_name>Hecoria</other_name>
    <other_name>Prograf</other_name>
    <other_name>Protopic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Group I (haploidentical donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group III (haploidentical donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group V (haploidentical donor transplant, chemotherapy)</arm_group_label>
    <arm_group_label>Group VI (matched or haploidentical transplant, chemotherapy)</arm_group_label>
    <other_name>1,1'',1''''-Phosphinothioylidynetrisaziridine</other_name>
    <other_name>Girostan</other_name>
    <other_name>N,N'', N''''-Triethylenethiophosphoramide</other_name>
    <other_name>Oncotiotepa</other_name>
    <other_name>STEPA</other_name>
    <other_name>Tepadina</other_name>
    <other_name>TESPA</other_name>
    <other_name>Tespamin</other_name>
    <other_name>Tespamine</other_name>
    <other_name>Thio-Tepa</other_name>
    <other_name>Thiofosfamide</other_name>
    <other_name>Thiofozil</other_name>
    <other_name>Thiophosphamide</other_name>
    <other_name>Thiophosphoramide</other_name>
    <other_name>Thiotef</other_name>
    <other_name>Tifosyl</other_name>
    <other_name>TIO TEF</other_name>
    <other_name>Tio-tef</other_name>
    <other_name>Triethylene thiophosphoramide</other_name>
    <other_name>Triethylenethiophosphoramide</other_name>
    <other_name>Tris(1-aziridinyl)phosphine sulfide</other_name>
    <other_name>TSPA</other_name>
    <other_name>WR 45312</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with high-risk hematologic malignancies with anticipated poor prognosis with
             non transplant therapy, including those in remission or with induction failure and
             after treated or untreated relapse; Diagnoses to be included a) Acute myeloid
             leukemia; b) Acute lymphocytic leukemia; c) Chronic myeloid leukemia; d) Chronic
             lymphoproliferative disorder; e) Myelodysplastic syndrome; f) Myeloproliferative
             syndromes; g) Non-Hodgkin's lymphoma; h) Hodgkin's Lymphoma; i) Multiple myeloma

          -  Patients must have a haploidentical related donor or a fully matched related or
             unrelated donor

          -  Performance score of &gt;= 70 by Karnofsky/Lansky or performance score (PS) 0 to 1
             (Eastern Cooperative Oncology Group [ECOG] =&lt; 1)

          -  Left ventricular ejection fraction &gt;= 50%

          -  Adequate pulmonary function with forced expiratory volume in 1 second (FEV1), forced
             vital capacity (FVC) and diffusion capacity of the lung for carbon monoxide (DLCO) &gt;=
             50% of expected corrected for hemoglobin and/or volume; children unable to perform
             pulmonary function tests (e.g., less than 7 years old) pulse oximetry of &gt;= 92% on
             room air

          -  Creatinine clearance (calculated creatinine clearance by Cockcroft-Gault using
             adjusted body weight if actual body weight is 20% greater than ideal is permitted)
             should be &gt; 50 ml/min

          -  Bilirubin =&lt; 2 x the upper limit of normal (except with patients high indirect
             bilirubin due to Gilbert's syndrome, hypersplenism, or hemolysis)

          -  Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) &lt; 200

          -  Negative beta human chorionic gonadotropin (HCG) test in a woman with child bearing
             potential, defined as not post-menopausal for 12 months or no previous surgical
             sterilization; women of child bearing potential must be willing to use an effective
             contraceptive measure while on study

          -  Patient or patient's legal representative able to sign informed consent

        Exclusion Criteria:

          -  Human immunodeficiency virus (HIV) seropositivity

          -  Uncontrolled infections

          -  Patients with comorbidity score &gt; 3; the principal investigator is the final arbiter
             of eligibility for comorbidity score &gt; 3

          -  Prior allogeneic transplant

          -  Patients with active hepatitis B and C

          -  Patients with prior coronary artery disease

          -  Patients who received inotuzumab and/or gemtuzumab in the past
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Uday R Popat</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 5, 2016</study_first_submitted>
  <study_first_submitted_qc>August 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2016</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

